Passage Bio, Inc. (PASG) Q2 2021 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you for holding. Good morning and welcome to the PassageBio second quarter 2021 financial and operating results conference call. At this time, all participants are in a listen-only mode. Following the formal remarks, we will open the call up for your questions. Please be advised this call is being recorded at the company's request. At this time, I would like to turn it over to Stuart Henderson, Vice President of Investor Relations and Strategic Finance. Stuart, please begin. lines to topics we plan to discuss today. This release is available on the PassageBio website at investors.passagebio.com under the Press Releases and Statements section. On today's call, Bruce Goldsmith, President and Chief Executive Officer, will review our second quarter 2021 financial results and discuss recent business highlights. Eliseo Salinas, our Chief R&D Officer, will review our key clinical updates, and Jill Quigley, Our chief operating officer will also be available for the Q&A portion of the call. Before we begin, please note that today's call may include a number of forward-looking statements, including but not limited to comments on our expectations about timing and execution of anticipated milestones, including the initiation of clinical trials and the availability of clinical data from such trials, our expectations about our collaborators' and partners' ability to execute key initiatives, the ability of our lead product candidates to treat their respective target CNS disorder, manufacturing plans and strategies, trends with respect to financial performance and cash flows, the company's ability to fund research and development programs, impacts of the COVID-19 pandemic on the company's operations, and its ability to manage costs along with uses of cash and other matters. Th...